{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"32.1","upperLimit":"51.9","value":"41.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"103"}],"units":"Participants"}],"description":"Objective response was defined as proportion of participants who had achieved best overall response of PR or CR per RECIST v1.1. CR was defined as a disappearance of all target lesions. Any pathological lymph nodes (target or non-target) must had reduction in short axis to \\<10 mm and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. The Phase 2 evaluation of objective response was based on central independent CT/MRI image assessment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with iCCA with tumors harboring FGFR2 gene rearrangements received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"OG000","title":"Phase 2"}],"paramType":"NUMBER","populationDescription":"Efficacy population included all treated iCCA participants with confirmed FGFR2 gene fusions or other FGFR2 rearrangements who had received at least 1 dose of TAS-120.","reportingStatus":"POSTED","timeFrame":"Up to approximately 37.5 months (through cut-off date 29-May-2021)","title":"Phase 2: Percentage of Participants With Objective Response","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}